Clinical Trial

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 5, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Jaktinib in subjects with active Ankylosing Spondylitis(AS).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-05-06; most recent amendment 2025-12-30.
Status change: Recruiting → Active, Not Recruiting 2025-12-30
Status change: Not Yet Recruiting → Recruiting 2023-07-24
Trial Details
NCT Number NCT05861102
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Ankylosing Spondylitis
Enrollment 265 participants
Start Date 2023-07-20
Primary Completion 2026-05 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-05